Nurix Therapeutics Inc. (NRIX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to a loss of $0.52 per share a year ago.
Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Decline
Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade
The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 29.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Nurix Stock Up 29% in a Month: Here's What You Should Know
NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront payment and potential milestone payouts of up to $2.3 billion.
Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?
Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated Diseases Transcript
Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated Diseases Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 85.8% in Nurix Therapeutics (NRIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide
Nurix Therapeutics, Inc. maintains a Strong Buy rating, driven by the advancement of bexobrutideg for relapsed/refractory CLL in pivotal phase 2 trials. Company is set to initiate a global phase 3 confirmatory trial for bexobrutideg in mid-2026, targeting patients post-BTK therapy and benchmarking against pirtobrutinib. Expansion efforts include higher-dose bexobrutideg for earlier CLL lines, an oral formulation for immunology, and the dual BTK/IKZF degrader zelebrudomide for B-cell malignancies.
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $0.67 per share a year ago.
